$Eli Lilly(LLY)$ is experiencing a notable correction today, driven by disappointing Q4 sales guidance. The company's expected sales of $13.5B fell short of consensus estimates ($14B), with underwhelming performances from Zepbound (obesity) and Mounjaro (diabetes).
I've learned to recalibrate my perspective on such events. Rather than succumbing to fear, I recognize opportunities to buy the dip as a prudent long-term strategy.
Notably, LLY serves as a strategic diversification component in my portfolio, providing a relatively stable hedge against the volatility inherent in my technology and cryptocurrency holdings. This allocation helps balance risk and potential returns, underscoring the importance of thoughtful portfolio construction.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
- UrsulaFowler·01-15Buy the dip1Report